Olanzapine Market Report 2026

The olanzapine market size has grown steadily in recent years. It will grow from $2.63 billion in 2025 to $2.71 billion in 2026 at a compound annual growth rate (CAGR) of 2.8%. The growth in the historic period can be attributed to increasing prevalence of schizophrenia and bipolar disorder, early clinical efficacy of atypical antipsychotics, physician preference for broad-spectrum antipsychotics, expansion of hospital-based psychiatric care, favorable reimbursement for mental health drugs.

The olanzapine market size is expected to see steady growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to growth in global mental health awareness, rising adoption of combination drug therapies, expanding access to psychiatric care in emerging economies, development of improved olanzapine formulations, increasing focus on treatment adherence. Major trends in the forecast period include rising use of long-acting injectable olanzapine, growing preference for orally disintegrating tablets, expansion of combination therapies in bipolar disorder, increasing generic penetration in emerging markets, shift toward home-based mental health management.

The rising prevalence of emotional illnesses and mental health disorders is expected to drive the growth of the olanzapine market in the coming years. Emotional illness and mental disorders are conditions that affect an individual’s mental and emotional well-being. The growing incidence of emotional and mental health issues is increasing the demand for effective mental health treatment options, including olanzapine, an atypical antipsychotic primarily used to treat conditions such as schizophrenia and bipolar disorder and sometimes prescribed alongside other medications for the treatment of depression. For instance, in May 2024, according to the American Psychiatric Association, a US-based professional organization, the proportion of adults reporting increased anxiety rose from 32% in 2022 to 37% in 2023 and further to 43% in 2024. Therefore, the increasing prevalence of emotional illness and mental health disorders is contributing to the growth of the olanzapine market.

Leading companies operating in the olanzapine market are adopting strategic partnership models to introduce olanzapine as a long-acting treatment option with an improved safety profile. Strategic partnerships involve companies collaborating by combining their resources and expertise to achieve shared objectives and mutual benefits. For example, in November 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, entered into a partnership with Royalty Pharma PLC, a US-based biopharmaceutical company. Through this collaboration, the companies aim to accelerate the clinical development program for Teva’s olanzapine LAI (TEV-‘749), a once-monthly subcutaneous long-acting injectable formulation of the atypical antipsychotic olanzapine that is currently in Phase 3 clinical trials for the treatment of schizophrenia.

In April 2023, Cheplapharm Arzneimittel GmbH, a Germany-based pharmaceutical company involved in branded medicines, medical products, supplements, and cosmetics, acquired the worldwide commercial rights to Zyprexa from Eli Lilly and Company for an undisclosed sum. This acquisition enabled Cheplapharm to strengthen its portfolio in the central nervous system therapeutic area. Eli Lilly and Company is a US-based pharmaceutical company engaged in the development and commercialization of olanzapine medications.

Major companies operating in the olanzapine market are Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Torrent Group, Apotex Inc., Mylan N.V., Viatris Inc., Zydus Cadila Healthcare Ltd., Endo International plc, Lupin Limited, Cipla Inc., Eli Lilly and Company, Zhejiang Langhua Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Sandoz International GmbH, Changzhou Huasheng Pharmaceutical Co. Ltd., Par Pharmaceutical, Jubilant Pharmova Limited, Hansoh Pharmaceutical, Egis Pharmaceuticals plc, Actavis Group hf., Hexal AG.

North America was the largest region in the olanzapine market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global olanzapine market report during the forecast period. The regions covered in the olanzapine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the olanzapine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the olanzapine market by increasing the cost of active pharmaceutical ingredients, excipients, and injectable formulation supplies sourced through global trade. These cost pressures are most visible in parenteral formulations and combination therapies, with Asia-Pacific and parts of Europe being most affected due to their dependence on cross-border pharmaceutical supply chains. Hospitals and specialty clinics experience pricing sensitivity as procurement costs rise, while generic manufacturers face margin pressures. On the positive side, tariffs are encouraging localized drug manufacturing, regional API sourcing, and supply chain resilience, which may strengthen long-term market stability.

The olanzapine market research report is one of a series of new reports that provides olanzapine market statistics, including olanzapine industry global market size, regional shares, competitors with a olanzapine market share, detailed olanzapine market segments, market trends and opportunities, and any further data you may need to thrive in the olanzapine industry. This olanzapine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Olanzapine is an atypical antipsychotic drug used to manage several mental health conditions, including schizophrenia, bipolar disorder, and depression associated with bipolar disorder. It functions by regulating the activity of specific brain chemicals, particularly dopamine and serotonin.

The primary types of olanzapine treatment include monotherapy and combination therapy. Monotherapy refers to a treatment approach in which a single medication, such as olanzapine, is used alone to manage a specific condition, including schizophrenia, bipolar disorder, and major depressive disorder. In olanzapine monotherapy, the drug is administered without being combined with other medications. These treatments are delivered through oral and parenteral routes to manage schizophrenia, bipolar disorder, and related conditions and are provided by hospitals, home care settings, specialty clinics, and other end users.

The olanzapine market consists of sales of branded and generic olanzapine medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.